Skip to main content

Table 1 Baseline characteristics of subjects

From: Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study

Variable

NBC

(n = 66)

Obesity

(n = 59)

Sarcopenia

(n = 54)

Sarcopenic Obesity

(n = 19)

P-value

Demographics

Age, years

63.63 ± 8.78

64.85 ± 8.48

68.47 ± 6.68

71.27 ± 8.52*

0.012

Sex, m/f (%)

47/19

47/12

36/18

10/9

0.126

Pulmonary function

FEV1, %predicted

1.78 ± 0.59

1.72 ± 0.65

1.31 ± 0.55*, #

1.29 ± 0.63*, #

0.002

FEV1/FVC, %

57.90 ± 8.55

56.61 ± 9.29

52.34 ± 11.84

54.21 ± 8.99

0.106

Physical function

     

6MWD, m

410.2 ± 50.31

397.6 ± 68.70

322.4 ± 34.37*, #

267.7 ± 82.97*, #, &

< 0.001

5STS, s

6.43 ± 1.94

6.48 ± 1.29*

8.94 ± 2.21*, #

11.84 ± 2.20*, #, &

< 0.001

Body composition

BMI, kg/m2

22.01 ± 2.21

27.92 ± 2.66

21.09 ± 3.15

27.17 ± 2.54

< 0.001

Body fat (%)

26.08 ± 6.28

31.77 ± 4.49*, &

27.19 ± 5.92#

34.95 ± 4.72*, &

< 0.001

FFMI (kg/m2)

16.88 ± 1.28

18.76 ± 1.63*

14.89 ± 2.23*, &

14.29 ± 2.50*, &

< 0.001

SMMI (kg/m2)

28.37 ± 3.52

26.75 ± 2.80

26.21 ± 2.81*,

23.90 ± 2.54*, &

< 0.001

  1. NBC, Normal Body Composition
  2. Values are given as percentage, mean (SD), or median (interquartile range) and χ2, 1-way ANOVA, or Kruskal–Wallis ANOVA on Ranks, P-values are indicated respectively, as appropriate
  3. *P < 0.05 compared with normal body composition
  4. #P < 0.05 compared with obesity
  5. &P < 0.05 compared with sarcopenia